GAMA reveals plans for £2m R&D facility

GAMA Healthcare, a leader in the manufacture and development of infection prevention products for the healthcare sector, has outlined plans to build a new research and development facility in the Greetland area of Halifax.

The proposed development, spread across 11,765 sq ft, is projected to cost £2 million and comprises a contemporary open-office environment with advanced research laboratories and auxiliary space to produce and test product samples.

Managing director and co-founder of GAMA Healthcare, Dr Guy Braverman said: “Plans for the new R&D facility are geared towards facilitating an up-to-date environment for research and innovation breakthroughs with industry leading practices. The laboratories will be capable of conducting detailed up-to-date research in all aspects of microbiology, infection control and analytical chemistry. A pilot plant is being incorporated to allow experimental small product runs enabling our teams to conduct trials and be proactive with quality assurance and internal testing. The facility will also incorporate a mock hospital room to replicate real life scenarios.”

 

Other news

Upcoming Events

NPAG - Clinical Engineering and IT Connectivity Conference 2017

Ricoh Arena - Coventry
12th September 2017

Infection Prevention 2017

Manchester Central Convention Complex
18th - 20th September

QIST 2017

The Marriott Hotel Gosforth Newcastle
17th - 18th October

MEDICA

Düsseldorf
13 - 16 November 2017

IDSc CONFERENCE 2016

The Hilton, Blackpool
27th - 29th November

Latest Issue

Clinical Services Journal

Clinical Services Journal

Aug 2017

Partnership helps surgeons heal wounds

Register now to apply for regular copies of Clinical Services Journal and free access to premium content, as well as our regular newsletters.

CSJ Supplements

CSJ Supplements

Aug 2017

Technology with the vision to make surgery better

Register now to apply for regular copies of CSJ Supplements and free access to premium content, as well as our regular newsletters.